Alemtuzumab is a monoclonal antibody currently already used in the treatment of chronic lymphocytic leukemia and T-cell lymphoma. Results from the phase II study comparing it to Rebif were published in May 2007 showing efficacy. However, the trial was halted after 3 cases of immune thrombocytopenic purpura (ITP) were reported; later on, a further 3 more cases were found, and 1 patient died. This is a life-threatening side-effect but is treatable if detected.
| Property | Value |
|---|
| dbpprop:abstract
|
- Alemtuzumab is a monoclonal antibody currently already used in the treatment of chronic lymphocytic leukemia and T-cell lymphoma. Results from the phase II study comparing it to Rebif were published in May 2007 showing efficacy. However, the trial was halted after 3 cases of immune thrombocytopenic purpura (ITP) were reported; later on, a further 3 more cases were found, and 1 patient died. This is a life-threatening side-effect but is treatable if detected. Therefore, all patients receiving alemtuzumab should have their platelet count monitored.
|
| dbpprop:hasPhotoCollection
| |
| dbpprop:reference
| |
| rdf:type
| |
| rdfs:comment
|
- Alemtuzumab is a monoclonal antibody currently already used in the treatment of chronic lymphocytic leukemia and T-cell lymphoma. Results from the phase II study comparing it to Rebif were published in May 2007 showing efficacy. However, the trial was halted after 3 cases of immune thrombocytopenic purpura (ITP) were reported; later on, a further 3 more cases were found, and 1 patient died. This is a life-threatening side-effect but is treatable if detected.
|
| rdfs:label
|
- Therapies under investigation for multiple sclerosis
|
| owl:sameAs
| |
| skos:subject
| |
| foaf:page
| |
| is dbpprop:list
of | |
| is dbpprop:redirect
of | |
| is owl:sameAs
of | |
![[RDF Data]](/statics/sw-cube.png)
